Patents Assigned to ImmunEdge, Inc.
  • Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein
    Patent number: 12637513
    Abstract: The present disclosure provides EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. Also provided herein are engineered EPOs. The EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and/or engineered EPOs can be used to treat patients.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: May 26, 2026
    Assignees: ImmunEdge, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Bo Yu, Edgar G. Engleman, Xiangyue Zhang, David Kung-Chun Chiu
  • Antibodies that inhibit erythropoietin receptor activation and methods of use thereof to treat cancer
    Patent number: 12637514
    Abstract: The present disclosure provides anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. The anti-EPOR antibodies, anti-EPO antibodies, and/or engineered EPOs can be used to treat patients.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: May 26, 2026
    Assignees: ImmunEdge, Inc., The Board of Trustees of the Leland Stanford University
    Inventors: Bo Yu, Edgar G. Engleman, Xiangyue Zhang, David Kung-Chun Chiu
  • Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein
    Patent number: 12540189
    Abstract: The present disclosure provides EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. Also provided herein are engineered EPOs. The EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and/or engineered EPOs can be used to treat patients.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: February 3, 2026
    Assignees: ImmunEdge, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Bo Yu, Edgar G. Engleman, Xiangyue Zhang, David Kung-Chun Chiu